RET inhibitor TPX-0046 in the treatment of tumors, phase I/II SWORD-1 phase study has obtained preliminary clinical data

Turning Point Therapeutics is a precision oncology company dedicated to the development of next-generation therapies that target the genetic drivers of cancer.

The preliminary data in the phase I dose finding part of the study showed preliminary clinical activity, including objective response and generally well-tolerated safety.

Alexander Drilon, General Manager of Early Drug Development Services at Memorial Sloan Kettering Hospital Cancer Center, said: "In the United States and the European Union, RET-driven cancer affects nearly 10,000 patients each year, and treatment with selective RET inhibitors progresses.

The 21 patients included in the study included 10 cases of non-small cell lung cancer ( NSCLC ) and 11 cases of medullary thyroid carcinoma (MTC).

Among the 5 patients who did not undergo RET TKI, 4 showed tumor regression rates of -42%, -37%, -23%, and -3%.

Original source:

href="" target="_blank" rel="noopener">